Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 97 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016', provides an overview of the Varicella Zoster (HHV-3) Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Varicella Zoster (HHV-3) Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections
- The report reviews pipeline therapeutics for Varicella Zoster (HHV-3) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Varicella Zoster (HHV-3) Infections therapeutics and enlists all their major and minor projects
- The report assesses Varicella Zoster (HHV-3) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Varicella Zoster (HHV-3) Infections

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Varicella Zoster (HHV-3) Infections Overview 9
Therapeutics Development 10
Pipeline Products for Varicella Zoster (HHV-3) Infections - Overview 10
Pipeline Products for Varicella Zoster (HHV-3) Infections - Comparative Analysis 11
Varicella Zoster (HHV-3) Infections - Therapeutics under Development by Companies 12
Varicella Zoster (HHV-3) Infections - Therapeutics under Investigation by Universities/Institutes 14
Varicella Zoster (HHV-3) Infections - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Varicella Zoster (HHV-3) Infections - Products under Development by Companies 19
Varicella Zoster (HHV-3) Infections - Products under Investigation by Universities/Institutes 20
Varicella Zoster (HHV-3) Infections - Companies Involved in Therapeutics Development 21
Astellas Pharma Inc. 21
Beijing Minhai Biotechnology Co., Ltd 22
Beijing Tiantan Biological Products Co., Ltd. 23
ContraVir Pharmaceuticals, Inc. 24
Epiphany Biosciences, Inc. 25
Foamix Pharmaceuticals Ltd. 26
GeneOne Life Science, Inc. 27
GlaxoSmithKline Plc 28
Green Cross Corporation 29
Merck & Co., Inc. 30
N & N Pharmaceuticals Inc. 31
NAL Pharmaceuticals Ltd. 32
NanoViricides, Inc. 33
ReceptoPharm, Inc. 34
Sinovac Biotech Ltd. 35
SK Chemicals Co., Ltd. 36
TSRL, Inc. 37
XBiotech Inc 38
Zydus Cadila Healthcare Limited 39
Varicella Zoster (HHV-3) Infections - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
(measles + mumps + rubella + varicella) vaccine - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
(measles + rubella + varicella) vaccine - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
acyclovir - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
amenamevir - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
chickenpox vaccine - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
FV-100 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
GLS-5100 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
GSK-1437173A - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
herpes zoster vaccine - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
HHV-3 vaccine - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
measles + mumps + rubella + varicella vaccine - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
MG-1111 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Monoclonal Antibody for Shingles - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
NAL-3221 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
NAL-3223 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
NBP-608 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
NN-001 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
RKP-00156 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
RPI-78M - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
sattabacin - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Small Molecule for Shingles - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
TSR-087 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
V-212 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
valomaciclovir stearate - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
varicella zoster vaccine - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Varicella Zoster (HHV-3) Infections - Dormant Projects 83
Varicella Zoster (HHV-3) Infections - Discontinued Products 84
Varicella Zoster (HHV-3) Infections - Product Development Milestones 85
Featured News & Press Releases 85
Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM 85
Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles 86
Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug 87
Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study 87
Oct 27, 2015: GSK's candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over 88
Oct 26, 2015: Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate 89
Sep 08, 2015: Clinical trial for Cardiff's shingles treatment 89
Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain 90
Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial 91
Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied 91
Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN 92
Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint 93
Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant 94
Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles 94
Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 96
Disclaimer 97

List of Tables

Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2016 10
Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Comparative Analysis by Unknown Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Investigation by Universities/Institutes, H2 2016 20
Varicella Zoster (HHV-3) Infections - Pipeline by Astellas Pharma Inc., H2 2016 21
Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 22
Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016 23
Varicella Zoster (HHV-3) Infections - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 24
aricella Zoster (HHV-3) Infections - Pipeline by Epiphany Biosciences, Inc., H2 2016 25
Varicella Zoster (HHV-3) Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 26
Varicella Zoster (HHV-3) Infections - Pipeline by GeneOne Life Science, Inc., H2 2016 27
Varicella Zoster (HHV-3) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 28
Varicella Zoster (HHV-3) Infections - Pipeline by Green Cross Corporation, H2 2016 29
Varicella Zoster (HHV-3) Infections - Pipeline by Merck & Co., Inc., H2 2016 30
Varicella Zoster (HHV-3) Infections - Pipeline by N & N Pharmaceuticals Inc., H2 2016 31
Varicella Zoster (HHV-3) Infections - Pipeline by NAL Pharmaceuticals Ltd., H2 2016 32
Varicella Zoster (HHV-3) Infections - Pipeline by NanoViricides, Inc., H2 2016 33
Varicella Zoster (HHV-3) Infections - Pipeline by ReceptoPharm, Inc., H2 2016 34
Varicella Zoster (HHV-3) Infections - Pipeline by Sinovac Biotech Ltd., H2 2016 35
Varicella Zoster (HHV-3) Infections - Pipeline by SK Chemicals Co., Ltd., H2 2016 36
Varicella Zoster (HHV-3) Infections - Pipeline by TSRL, Inc., H2 2016 37
Varicella Zoster (HHV-3) Infections - Pipeline by XBiotech Inc, H2 2016 38
Varicella Zoster (HHV-3) Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 39
Assessment by Monotherapy Products, H2 2016 40
Assessment by Combination Products, H2 2016 41
Number of Products by Stage and Target, H2 2016 43
Number of Products by Stage and Mechanism of Action, H2 2016 45
Number of Products by Stage and Route of Administration, H2 2016 47
Number of Products by Stage and Molecule Type, H2 2016 49
Varicella Zoster (HHV-3) Infections - Dormant Projects, H2 2016 83
Varicella Zoster (HHV-3) Infections - Discontinued Products, H2 2016 84